Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Zerit Xr Patent Expiration

Zerit Xr is a drug owned by Bristol Myers Squibb Co. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 18, 2023. Details of Zerit Xr's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7135465

(Pediatric)

 Sustained release beadlets containing stavudine
Aug, 2023

(1 year, 8 months ago)

Expired
US7135465 Sustained release beadlets containing stavudine
Feb, 2023

(2 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Zerit Xr's patents.

Given below is the list of recent legal activities going on the following patents of Zerit Xr.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 03 May, 2018 US7135465
Post Issue Communication - Certificate of Correction 21 Aug, 2007 US7135465
Recordation of Patent Grant Mailed
Critical
 14 Nov, 2006 US7135465
Patent Issue Date Used in PTA Calculation
Critical
 14 Nov, 2006 US7135465
Issue Notification Mailed
Critical
 25 Oct, 2006 US7135465
Application Is Considered Ready for Issue
Critical
 18 Oct, 2006 US7135465
Dispatch to FDC 18 Oct, 2006 US7135465
Issue Fee Payment Received
Critical
 13 Oct, 2006 US7135465
Issue Fee Payment Verified
Critical
 13 Oct, 2006 US7135465
Mail Notice of Allowance
Critical
 18 Jul, 2006 US7135465

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Zerit Xr is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Zerit Xr's family patents as well as insights into ongoing legal events on those patents.

Zerit Xr's Family Patents

Zerit Xr has patent protection in a total of 24 countries. It's US patent count contributes only to 11.5% of its total global patent coverage. 21 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Zerit Xr.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Zerit Xr's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 18, 2023 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Zerit Xr Generic API suppliers:

Stavudine is the generic name for the brand Zerit Xr. 4 different companies have already filed for the generic of Zerit Xr, with Norvium Bioscience having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Zerit Xr's generic

Alternative Brands for Zerit Xr

Zerit Xr which is used for managing HIV-1 infection., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Bristol
Evotaz Used for treating HIV-1 infection by including a pharmacokinetic enhancer that inhibits cytochrome P450 monooxygenase.
Bristol Myers Squibb
Reyataz Used for treating HIV-1 infection.





About Zerit Xr

Zerit Xr is a drug owned by Bristol Myers Squibb Co. It is used for managing HIV-1 infection. Zerit Xr uses Stavudine as an active ingredient. Zerit Xr was launched by Bristol Myers Squibb in 2002.

Approval Date:

Zerit Xr was approved by FDA for market use on 31 December, 2002.

Active Ingredient:

Zerit Xr uses Stavudine as the active ingredient. Check out other Drugs and Companies using Stavudine ingredient

Treatment:

Zerit Xr is used for managing HIV-1 infection.

Dosage:

Zerit Xr is available in capsule, extended release form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
100MG CAPSULE, EXTENDED RELEASE Discontinued ORAL
50MG CAPSULE, EXTENDED RELEASE Discontinued ORAL
75MG CAPSULE, EXTENDED RELEASE Discontinued ORAL
37.5MG CAPSULE, EXTENDED RELEASE Discontinued ORAL